Barely Significant
← all excerpts

Combination of Empagliflozin and Metformin Therapy: A Consideration of its Place in Type 2 Diabetes Therapy.

Clin Med Insights Endocrinol Diabetes · 2018 · PMC6043932 · PMID 30013414

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

of borderline significanceP = .05actually significant
Diastolic BP was also reduced from baseline to week 52, but the difference between empagliflozin 25 mg/linagliptin 5 mg (−2.2 mm Hg) and empagliflozin 10 mg/linagliptin 5 mg (−2.2 mm Hg) compared with linagliptin monotherapy (−0.6 mm Hg) was only of borderline significance ( P = .05) and was similar to empagliflozin monotherapy (−1.9 mm Hg [25 mg] and 1.8 mm Hg [10 mg]).

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.